313 related articles for article (PubMed ID: 8678066)
1. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin.
Moreno F; Aracil FJ; Pérez R; Valderrábano F
Am J Kidney Dis; 1996 Apr; 27(4):548-56. PubMed ID: 8678066
[TBL] [Abstract][Full Text] [Related]
2. Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin.
Tarng DC; Huang TP; Doong TI
Nephron; 1998; 78(3):253-9. PubMed ID: 9546682
[TBL] [Abstract][Full Text] [Related]
3. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group.
Laupacis A; Wong C; Churchill D
Control Clin Trials; 1991 Aug; 12(4 Suppl):168S-179S. PubMed ID: 1663853
[TBL] [Abstract][Full Text] [Related]
4. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
Ifudu O; Feldman J; Friedman EA
N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
[TBL] [Abstract][Full Text] [Related]
5. Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin.
González-Ortiz A; Correa-Rotter R; Vázquez-Rangel A; Vega-Vega O; Espinosa-Cuevas Á
BMC Nephrol; 2019 Aug; 20(1):316. PubMed ID: 31412807
[TBL] [Abstract][Full Text] [Related]
6. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients.
Beusterien KM; Nissenson AR; Port FK; Kelly M; Steinwald B; Ware JE
J Am Soc Nephrol; 1996 May; 7(5):763-73. PubMed ID: 8738812
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
[TBL] [Abstract][Full Text] [Related]
8. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model.
Messana JM; Chuang CC; Turenne M; Wheeler J; Turner J; Sleeman K; Tedeschi P; Hirth R
Am J Kidney Dis; 2009 Mar; 53(3):503-12. PubMed ID: 19185402
[TBL] [Abstract][Full Text] [Related]
9. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology.
Moreno F; Sanz-Guajardo D; López-Gómez JM; Jofre R; Valderrábano F
J Am Soc Nephrol; 2000 Feb; 11(2):335-342. PubMed ID: 10665941
[TBL] [Abstract][Full Text] [Related]
10. Severity of AIDS and the response to EPO in uremia.
Ifudu O; Matthew JJ; Mayers JD; Macey LJ; Brezsnyak W; Reydel C; McClendon E; Surgrue T; Rao S; Friedman EA
Am J Kidney Dis; 1997 Jul; 30(1):28-35. PubMed ID: 9214398
[TBL] [Abstract][Full Text] [Related]
11. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
Ballal SH; Domoto DT; Polack DC; Marciulonis P; Martin KJ
Am J Kidney Dis; 1991 Jan; 17(1):29-33. PubMed ID: 1986567
[TBL] [Abstract][Full Text] [Related]
12. Use of erythropoietin before the initiation of dialysis and its impact on mortality.
Fink J; Blahut S; Reddy M; Light P
Am J Kidney Dis; 2001 Feb; 37(2):348-55. PubMed ID: 11157377
[TBL] [Abstract][Full Text] [Related]
13. Management of anemia with quotidian hemodialysis.
Rao M; Muirhead N; Klarenbach S; Moist L; Lindsay RM
Am J Kidney Dis; 2003 Jul; 42(1 Suppl):18-23. PubMed ID: 12830439
[TBL] [Abstract][Full Text] [Related]
14. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin.
McMahon LP; Dawborn JK
Am J Nephrol; 1992; 12(3):162-9. PubMed ID: 1415377
[TBL] [Abstract][Full Text] [Related]
15. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
16. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.
Kuriyama S; Tomonari H; Yoshida H; Hashimoto T; Kawaguchi Y; Sakai O
Nephron; 1997; 77(2):176-85. PubMed ID: 9346384
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow changes following treatment of renal anemia with erythropoietin.
Horina JH; Schmid CR; Roob JM; Winkler HM; Samitz MA; Hammer HF; Pogglitsch H; Krejs GJ
Kidney Int; 1991 Nov; 40(5):917-22. PubMed ID: 1762296
[TBL] [Abstract][Full Text] [Related]
18. The effect of high-flux hemodialysis on renal anemia.
Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
[TBL] [Abstract][Full Text] [Related]
19. [Effect of the treatment with human recombinant erythropoietin on anemia in children with end-stage kidney failure. French multicenter study].
Sinnassamy P; Andre JL; Treize G; Leroy B
Arch Fr Pediatr; 1993 Mar; 50(3):201-8. PubMed ID: 8338412
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.
Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH
Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
